3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms

J Neural Transm. 1989;75(1):1-10. doi: 10.1007/BF01250639.

Abstract

In post-mortem putamen samples from 27 schizophrenics and 27 controls D2 receptors were measured by Scatchard analysis using 3H-spiperone as a ligand. Maximum number of binding sites (Bmax) and apparent dissociation constant (KD) were significantly increased only in patients in whom neuroleptic medication had been given within a three-month period before death. When the neuroleptic medication had been withdrawn at least 3 month before death, there was a slight, but not significant, reduction in Bmax values and unchanged KD values. Withdrawal of neuroleptic drugs was followed by a normalization of the KD values within 2 weeks and a slower reduction of Bmax values. There were 6 schizophrenic patients with mainly positive schizophrenic symptoms and 17 patients with mainly negative symptoms; positive schizophrenic symptoms were not related to higher Bmax values. There was no difference in 3H-spiperone binding between patients with and without movement disorders (tardive dyskinesia or extrapyramidal symptoms).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Dyskinesia, Drug-Induced / metabolism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Receptors, Dopamine / metabolism*
  • Receptors, Dopamine D2
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism*
  • Spiperone / metabolism*

Substances

  • Antipsychotic Agents
  • Receptors, Dopamine
  • Receptors, Dopamine D2
  • Spiperone